AUTL

Business Context and Reporting Period

Autolus Therapeutics Plc (Autolus) is an early commercial-stage biopharmaceutical company developing programmed T cell therapies for cancer and autoimmune diseases. This Form 10-Q covers the quarterly period ended September 30, 2024. Although Autolus qualifies as a Foreign Private Issuer and is exempt from mandatory 10-Q filings, it voluntarily elected to file this report. The Company's primary focus is the commercialization of AUCATZYL (obecabtagene autoleucel), which received U.S. FDA marketing approval on November 8, 2024, for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

Key Financial Metrics

Note: Revenue for the nine months ended September 30, 2024, was derived entirely from the BioNTech License and Option Agreement. No commercial product revenue has been generated as of the balance sheet date.

Material Changes vs. Prior Period

• Revenue: License revenue was $0 for the three months ended September 30, 2024, compared to $0.4 million in the same period in 2023. For the nine-month period, revenue increased to $10.1 million from $1.7 million in 2023, driven by the recognition of revenue from the BioNTech agreement.
• Operating Expenses: Total operating expenses increased by 58% year-over-year for the quarter (from $42.9 million to $67.9 million) and by 31% for the nine-month period (from $126.4 million to $165.6 million). This increase was primarily due to higher personnel costs, commercial-stage readiness activities, and increased clinical costs.
• Net Loss: Net loss increased by 79% for the quarter (from $45.8 million to $82.1 million) and by 47% for the nine-month period (from $131.2 million to $193.1 million). Significant contributors to the loss included a $11.9 million foreign exchange loss for the quarter and $10.7 million in interest expense.
• Liquidity: Cash and cash equivalents increased significantly from $239.6 million at December 31, 2023, to $657.1 million at September 30, 2024. This was driven by net proceeds of approximately $520.6 million from the issuance of ordinary shares in February 2024 (including an underwritten offering and a private placement with BioNTech).
• Interest Expense: Interest expense rose to $10.7 million for the quarter and $40.1 million for the nine months, compared to $5.0 million and $14.9 million in the prior year periods, respectively. This increase reflects the amortization of liabilities related to future royalties and milestones from the Blackstone and BioNTech agreements.

Guidance, Outlook, and Risks

Outlook and Management Commentary: Management expects to continue incurring operating losses in the foreseeable future. The Company believes its cash position of $657.1 million is sufficient to fund operations for at least the next twelve months. The recent FDA approval of AUCATZYL is a pivotal milestone, triggering a $30.0 million milestone payment from Blackstone (expected in Q4 2024) and obligating a £10.0 million ($13.4 million) regulatory milestone payment to UCLB (expected in Q1 2025). The Company is preparing for the commercial launch of AUCATZYL in the U.S. and has regulatory submissions pending in the EU and U.K.

Risks and Contingencies:

• Internal Controls: The Company identified a material weakness in internal control over financial reporting related to the accounting for complex transactions (specifically the BioNTech Agreements). Management is implementing a remediation plan.
• Capital Requirements: Despite the recent cash infusion, the Company will require significant additional capital to commercialize AUCATZYL and advance its pipeline. Future funding may not be available on acceptable terms.
• Regulatory and Commercialization: Success depends on market acceptance, reimbursement, and the ability to scale manufacturing. The Company faces competition from established CAR T therapies.
• Foreign Exchange: As a UK-based company reporting in USD, Autolus is exposed to significant foreign exchange volatility, which resulted in substantial losses in the current period.

Key Facts for Investor Verification

• FDA Approval Timing: Verify the commercial launch timeline for AUCATZYL following the November 8, 2024, FDA approval and the impact on revenue recognition.
• Milestone Payments: Confirm the receipt of the $30.0 million Blackstone milestone payment and the timing of the £10.0 million UCLB payment.
• Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness in internal controls over financial reporting.
• Cash Burn Rate: Assess the sustainability of the $657.1 million cash balance given the increased operating expenses associated with commercialization and the high interest expense on royalty liabilities.
• Foreign Exchange Exposure: Evaluate the Company's strategy for managing currency risk, given the significant foreign exchange losses recorded in the current period.